Back to today’s briefing

Story perspectives

Merck Q2 Revenue climbs, Keytruda hits $8.4 B, Outlook Raised

8/4/2026

40 4 Full Breakdown

Summary

Story summary

Merck posted Q2 revenue of $16.61 billion, up 5% YoY, and raised its 2026 outlook to $66.3-$67.3 billion.
Keytruda sales hit $8.37 billion, up 5%, with $463 million from the new QLEX injectable.
Merck recorded a GAAP loss of $1.34 billion and, according to CFO Caroline Litchfield, targets 30%-40% QLEX adoption in the United States by end-2027.

1 of 1

Story summary

Merck posted Q2 revenue of $16.61 billion, up 5% YoY, and raised its 2026 outlook to $66.3-$67.3 billion.
Keytruda sales hit $8.37 billion, up 5%, with $463 million from the new QLEX injectable.
Merck recorded a GAAP loss of $1.34 billion and, according to CFO Caroline Litchfield, targets 30%-40% QLEX adoption in the United States by end-2027.